QUALITY OF SLEEP IN PATIENTS WITH MYASTHENIA GRAVIS

Jelena Stojanov1,3, Aleksandar Stojanov2,3, Iva Binić3, Jovana Antonijević3, Martin Popević4,5

Myasthenia gravis (MG) is a chronic neuromuscular disease that leads to progressive weakness, fatigue of the skeletal muscles, and is often associated with psychological changes, especially with poorer quality of sleep.

To evaluate the quality of sleep in patients suffering from MG in relation to socio-demographic and clinical characteristics of the disease.

A total of 70 adult patients have been classified according to Myasthenia Gravis Foundation of America classification and divided into groups with regard to the age of onset, gender, employment status and type of work, presence or absence of pathological changes on thymus and presence or absence of anti-nAChr antibodies. Severity of clinical manifestations was evaluated by using quantitative MG scores and MG composite scores. Pittsburgh questionnaire was used to assess the subjective quality of sleep. In addition, Hamilton's anxiety and depression scales and questionnaires for quality of life assessment were also implemented.

The results of our research show a correlation between poor quality of sleep and prolonged duration of the disease, pathological changes on thymus, positive anti-nAChr antibodies. The correlation between poor quality of sleep with more severe clinical presentation, poor quality of life, anxiety and depression was confirmed.

Quality of sleep is impaired in patients with MG, especially in the case of severe clinical manifestations and prolonged duration of the disease. Considering the lack of literature on the subject, a better understanding of the prevalence and severity of sleep disorders in MG requires further research.

Acta Medica Medianae 2019;58(3):32-39.

Key words: myasthenia gravis, quality of sleep
sleep. Sleep quality disturbances are very often present in nearly all psychiatric disorders, particularly in depression and anxiety disorders (13). Little research was done on the relationship between the MG and the quality of sleep, and the interconnectedness is still not clear. It is a fact that evening exacerbations are more frequent in patients with MG, and that affects sleep. In addition, the impaired quality of sleep affects many domains of life in patients with MG. Therefore, it is very important to evaluate the quality of sleep and recognize early manifestations of sleep disorders in these patients.

**Aim**

The aim of this research was to evaluate the quality of sleep in patients suffering from MG, with regard to socio-demographic and clinical characteristics.

**Methods**

Study included 70 adult patients treated at the Neurology Clinic, Clinical Center Niš, from December 2016 to December 2017. The diagnosis of MG was made based on data from the patient history, examination, prostigmin and repetitive nerve stimulation test results, as well as by exclusion of other possible causes of symptoms presented. Data on sex, age of onset and current age, employment status, type of work, pathologically altered thymus and presence of anti-nAChr antibodies were collected. Severity of clinical manifestations was evaluated by using quantitative MG scores (QMG) (14) and MG composite scores (MGC) (15). The QMG is a 13-item scale that measures ocular, bulbar, respiratory and limb function. It evaluates each finding individually and results range from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits). MGC consists of 10 items and ranks the severity of MG at five levels in relation to the symptomatology and disorder of the affected muscle group function. The maximum score is 50, and the higher score reflects the more difficult form of clinical manifestation.

Patients were divided into groups according to the Myasthenia Gravis Foundation of America (MGFA) classification. Patients from MGFA group V on artificial ventilation were excluded from the study, as well as patients with other chronic illness that could affect the quality of sleep (diabetes, asthma, hypertension, heart failure, renal and hepatic insufficiency).

PSQI Quality of Sleep Assessment questionnaire consists of 19 self-rated questions. Components of the questionnaire measure quality of sleep, duration and latency of sleep, common efficacy of sleep, and functionality during the day. It assesses a 1-month interval and provides data useful both in clinical and scientific work. In addition to assessing the quality of sleep it provides clinically useful evaluation of variety of factors that might affect quality of sleep. These 19 questions are grouped into seven groups, each scored from 0-3. Obtained global PSQI score is from 0-21, where higher score indicates lower quality of sleep. It could be used as a tool for measuring interaction of sleep disturbances and depression, as well as relationship between sleep quality and other variables such as age, gender, health status, psychiatric and other medical conditions (13). It is so far the most used quality of sleep questionnaire (16), which is translated and standardized in Serbia (17). PSQI is easy to apply and understandable to patients, and it can potentially be used in everyday clinical practice.

In addition, the Hamilton scales for anxiety (HAM-A) and depression (HAM-D) and questionnaires "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items" - revised version (MGQOL15r) and Short Form Survey (SF-36), were used.

HAM-D measures the intensity of depression, and the values are interpreted as follows: 0-9 (without depression), 10-13 (mild depression), 14-17 (mild to moderate depression) and 18 or more (moderate to severe depression). HAM-A measures intensity of anxiety, where the ultimate values below 17 indicate absence or mild anxiety, values between 18-24 mild to moderate anxiety, and values between 25-30 moderate to severe anxiety.

The MGQOL15r questionnaire measures the quality of life specifically associated with myasthenia gravis. There is no pre-specified cutoff for classification of QoL in MG patients. It consists of 15 questions selected in 4 dimensions (mobility (8 questions), symptoms (3 questions), general contentment (2 questions), and emotional well-being (2 questions)). Each question is assessed from 0 to 4, and higher score represents more significant impact on quality of life.

The SF-36 questionnaire measures the quality of life associated with a general health condition, by including eight general health dimensions: physical functioning (PF), role functional physical (RP), bodily pain (BP), vitality (VT), social functioning (SF), role functioning emotional (RE), mental health (MH), general health (GH), and total score. The total scores for each of the eight dimensions ranged from 0 to 100 on the scale, were a higher score represents better health.

All patients signed an informed consent for participating in the study.

All data were statistically analyzed by IBM SPSS (version 21) for Windows operative system. Results with p < 0.05 were considered statistically significant. Numerical data were presented as means ± SD. The Mann-Whitney test was used to compare continuous variables between the two groups, and the Kruskal-Wallis test was used for comparison of more than two groups. Correlations were assessed using Pearson’s correlation coefficients or Spearman’s correlation coefficients.

**Results**

Epidemiological and clinical characteristics of 70 patients are presented in Table 1. The scores obtained by the used questionnaires are presented in Table 2.
Table 1. Demographic and clinical characteristics of MG patients

| Variable                                      | Value               |
|-----------------------------------------------|---------------------|
| Gender (number of patients)                   |                     |
| Male                                          | 33 (47.1 %)         |
| Female                                        | 37 (52.9 %)         |
| Current age (years) (Mean ± SD)               | 53.16 ± 15.98       |
| Disease duration (years) (Mean ± SD)          | 4.45 ± 4.4          |
| Profession (number of patients)               |                     |
| Physical workers                              | 16 (22.9 %)         |
| Intellectual workers                          | 13 (18.6 %)         |
| Unemployed                                    | 13 (18.6 %)         |
| Retired                                       | 28 (40.0 %)         |
| First MG symptoms (number of patients)        |                     |
| <50                                           | 35 (50%)            |
| ≥ 50                                          | 35 (50%)            |
| Thymus pathology (number of patients)         |                     |
| absent                                         | 25 (36%)            |
| present                                        | 45 (64%)            |
| Anti nAChR antibodies (number of patients)    |                     |
| absent                                         | 14 (20%)            |
| present                                        | 56 (80%)            |
| Current MGFA* (number of patients)            |                     |
| I                                             | 15 (21.4 %)         |
| IIa                                           | 11 (15.7 %)         |
| IIb                                           | 16 (22.9 %)         |
| IIIa                                          | 8 (11.5 %)          |
| IIIb                                          | 10 (14.4 %)         |
| IVa                                           | 6 (8.5 %)           |
| IVb                                           | 4 (5.7 %)           |
| QMG*(Mean score ± SD)                         | 8.16 ± 15.67        |
| MGC#(Mean score ± SD)                         | 7.51 ± 5.33         |

* Myasthenia Gravis Foundation of America (MGFA)
+ Quantitative myasthenia gravis score (QMG)
# Myasthenia gravis composite scores (MGC)

Table 2. Scores for all patients obtained on the used questionnaires

| Questionnaire                                      | Score ± SD          |
|----------------------------------------------------|---------------------|
| PSQI*                                              | 6.76 ± 4.60         |
| Hamilton scale for depression (Mean score ± SD)     | 10.29 ± 6.34        |
| Hamilton scale for anxiety (Mean score ± SD)        | 9.5 ± 6.9           |
| MGQOL15r                                           | 22.5 ± 11.53        |
| SF36 scores *                                      |                     |
| physical functioning                               | 58.28 ± 38.39       |
| role functional physical                           | 43.59 ± 49.6        |
| vitality                                          | 58.09 ± 47.71       |
| mental health                                      | 57.43 ± 25.23       |
| role functioning emotional                         | 65.37 ± 19.9        |
| social functioning                                 | 69.65 ± 26.28       |
| bodily pain                                        | 70.64 ± 26.52       |
| general health                                     | 50.28 ± 10.03       |
| Sum score                                          | 57.5 ± 24.7         |

* Pittsburgh Sleep Quality Index (PSQI)
** Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items **- revised version (MGQOL15r)
*Study Short Form of 36 questions (SF36)

(a) Differences in sleep quality in relation to different socio-demographic and clinical characteristics

In relation to gender, early or late onset of the disease, a statistically significant difference was not found in quality of sleep. Statistically significant difference with regard to quality of sleep exists in patients with pathological changes on the thymus, compared to the group of patients without these changes (p < 0.001). There is also a clear statistical difference between the groups with positive anti-nAChr antibodies (lower sleep quality) compared to the
group of seronegative patients (p<0.001). With regard to employment status and the type of work, the worst sleep quality was observed in physical workers, and the best in intellectual or administrative workers, with a statistically significant (p < 0.001) difference between the groups (Graph 1.).

(b) Correlation analysis between the severity of the clinical manifestation and the quality of sleep

In comparison with MGFA classification, patients with severe clinical presentation had the lowest quality of sleep, and this was more pronounced in groups with bulbar symptomatology, with statistically significant difference (Graph 2.).

In relation to the assessment of the severity of the clinical presentation, there is a clear correlation between more severe clinical manifestation and lower quality of sleep (Table 3.). Age and PSQI showed no clear correlation (p = 0.62), but the correlation was shown between the prolonged duration of disease and lower quality of sleep (p < 0.001).

Comparing other applied scales, a clear correlation was found between estimated lower quality of sleep and lower quality of life, anxiety and depres-
sion (Table 4.). Statistically significant correlation was shown between most of the sub-scales on the SF36 questionnaire and a questionnaire that assess the quality of sleep (for psychological functioning, role functioning emotional and general health p < 0.001; and for mental health, social functioning and bodily pain p < 0.05).

**Table 3. Correlation of sleep quality with duration of disease and severity of clinical picture**

| Duration of illness | MGC * | QMC # |
|---------------------|-------|-------|
| R       | p     | R    | p     | R    | p     |
| PSQI*   | 0.382 | <0.001** | 0.734 | <0.001** | 0.694 | <0.001** |

* Myasthenia gravis composite scores (MGC)
# Quantitative myasthenia gravis score (QMC)
* Pittsburgh Sleep Quality index (PSQI)

**Table 4. Correlation of sleep quality with quality of life, depression and anxiety**

| MGQOL15r * | SF36 # | Hamilton scale for depression | Hamilton scale for anxiety |
|------------|--------|-------------------------------|---------------------------|
| R           | p      | R                             | p                         |
| PSQI*       | 0.659  | <0.001**                      | -0.404                    |

* *Questionnaire of Life Quality Specific for Myasthnia Gravis - 15 items "- revised version (MGQOL15r)
# Study Short Form of 36 questions (SF36)
* Pittsburgh Sleep Quality Index (PSQI)

**Discussion**

In accordance with the aim of the study, the results show the correlation between poor quality of sleep and severity of clinical manifestation in MG, prolonged duration of the disease, pathological changes on thymus, the presence of positive anti-nAChr antibodies, poor quality of life and the presence of anxiety and depressive symptomatology in patients with MG.

Although daytime sleepiness and fatigue are common symptoms in neuromuscular diseases, there is not much data on the quality of sleep in these patients (18). Previous studies identified a higher prevalence of daytime sleepiness among MG patients (19, 20), while others found correlation only with the generalized type of the disease (21). Happe et al. (22) have found an association between the severity of clinical manifestations in MG and low quality of sleep, which is in line with the results of our research, while other studies have not established this association (6, 7). Studies that failed to find association between MG and poor quality of sleep had restriction in a form of small statistical samples (21, 23).

The results of our research show a correlation between lower quality of sleep and prolonged duration of the disease, which has never been examined, according to the available literature.

Tascilar et al. (24) found correlation between lower quality of life and PSQI scores only with regard to subjective sleep duration, and the results of our research have determined the correlation between the scores obtained on the PSQI questionnaire and the scores on the questionnaires that assess the quality of life (MG-QOL15). By using the SF-36 questionnaire for assessing the quality of life, Basta et al. (25) found negatively affected mental aspects of SF-36 in patients with MG, while the results of our research determined the correlation between the majority of the sub-scales on the SF-36 questionnaire and the PSQI questionnaire.

Sleep quality disturbances, including difficulty falling asleep or difficulty in maintaining sleep, are very often present in nearly all psychiatric disorders, particularly in depression and anxiety disorders (12). The weakness of skeletal musculature in patients with MG is often accompanied by depressive and anxiety symptomatology (26, 27), as well as impaired quality of life (28). In our research, lower quality of sleep correlated with the intensity of depressive and anxiety symptomatology in patients with MG. Some studies found no correlation between the duration of sleep and depression or anxiety (29), nor the correlation between the severity of MG and anxiety disorders (30).

Our results show association between pathological changes on thymus with poorer quality of sleep. The results also show correlation between
lower quality of sleep and presence of anti-nAChr antibodies, which has not been compared in previous research. Magni et al. (31) have not found association between psychiatric disturbances in MG with pathological changes on thymus, thymectomy, or age of MG onset, and also they did not evaluate the quality of sleep.

Most of these results indicate the significant role of MG in the daily functioning and the fulfillment of social tasks. This is the first study of quality of sleep in patients with MG in Serbia, based on relevant and validated sleep quality questionnaire. Restrictions include a small sample and the fact that we did not perform polysomnography to verify these patient-reported disturbances of sleep.

Conclusion

The results of our study showed a correlation between poor quality of sleep and prolonged duration of the disease. The link between pathological changes on thymus and the presence of positive anti-nAChr antibodies with poor quality of sleep was also demonstrated. Our results confirm the correlation between lower quality of sleep with more severe clinical presentation, poor quality of life and the presence of anxiety and depressive symptomatology in patients with MG. It is our suggestion that scale for assessing the quality of sleep (PSQI) should be used in the daily clinical work, considering that it is easily applied, understandable to patients and provides a clinically useful assessment of various factors that can affect quality of sleep. Considering the lack of literature on the subject, better understanding of the prevalence and severity of sleep disorders in MG requires further research.

References

1. Cruz-Martinez A. Conduction velocity along muscle fiber in situ in myasthenia gravis. Electroenceph Clin Neurophysiol 1996; 36:395-8. [PubMed]
2. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010; 18: 10-46. [CrossRef] [PubMed]
3. Lavrnic D, Basta I, Rakocvic-Stojanovic V, Stevic Z, Peric S, Nikolic A, et al. Epidemiological Study of Adult-Onset Myasthenia Gravis in the Area of Belgrade (Serbia) in the Period 1979–2008. Neuroepidemiology 2013; 40:190-4. [CrossRef] [PubMed]
4. Christensen PB, Jensen TS, Tsipoulos I, Sorensen T, Kjaer M, Højjer-Pedersen E, et al. Mortality and survival in myasthenia gravis: A Danish population based study. J Neurol Neurosurg Psychiatry 1998; 64(1):78-83. [CrossRef] [PubMed]
5. Schmidt-Nowara WW, Marder EJ, Feil PA. Respiratory failure in myasthenia gravis due to vocal cord paresis. Arch Neurol 1984; 41(5): 567-8. [CrossRef] [PubMed]
6. Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology 2006; 67:140-2. [CrossRef] [PubMed]
7. Prudlo J, Koenig J, Ermert S, Juh Asz J. Sleep disordered breathing in medically stable patients with myasthenia gravis. Eur J Neurol 2007; 14:321-6. [CrossRef] [PubMed]
8. Marlowe FI, D'Angelo AJ Jr. Respiratory failure as the initial presentation of myasthenia gravis. Ear Nose Throat J 1989; 68:472-3. [PubMed]
9. Paul RH, Nash JM, Cohen RA, Gilchris JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001; 24:512-6. [CrossRef] [PubMed]
10. Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, et al. Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurol Sci 2010; 31:41-5. [CrossRef] [PubMed]
11. Ybarra MI, Kummer A, Frota ERC, de Oliveira JT, Gomez RS, Teixeira AL. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 2011; 69(2):176-9. [CrossRef] [PubMed]
12. Stewart SB, Robertson KR, Johnson KM, Howard JF. The prevalence of depression in myasthenia gravis. J Clin Neuromusc Dis 2007; 8:111-5. [CrossRef]
13. Buysse DJ, Reynolds III CR, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A New
Quality of sleep in patients with myasthenia gravis

14. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998; 841:769-72. [CrossRef] [PubMed]

15. Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010; 74:1434-40. [CrossRef] [PubMed]

16. Mollayeva T, Thuraiarajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh Sleep Quality Index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and metaanalysis. Sleep Medicine Reviews 2016; 25:52-73. [CrossRef] [PubMed]

17. Popevic MB, Milovanovic APS, Milovanovic S, Nagorni-Obradovic Lj, Nesic D, Velaga M. Reliability and Validity of the Pittsburgh Sleep Quality Index-Serbian Translation. Eval Health Prof 2018; 41(1):67-81. [CrossRef] [PubMed]

18. Bourke SC, Gibson GJ. Sleep and breathing in neuromuscular disease. Eur Respir J 2002; 19:1194-201. [CrossRef] [PubMed]

19. Quera-Salva MA, Guillemainault C, Chevet S, Troche G, Fromageot C, Crowe McCann C, et al. Breathing disorders during sleep in myasthenia gravis. Ann Neurol 1992; 31:86-92. [CrossRef] [PubMed]

20. Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology 2006; 67:140-2. [CrossRef] [PubMed]

21. Martinez-Lapiscina EH, Erro ME, Ayuso T, Jerico I. Myasthenia Gravis: Sleep quality, quality of life and disease severity. Muscle Nerv 2012; 46(2):174-80. [CrossRef] [PubMed]

22. Happe S, Klosch G, Zeithofer J. Perception of dreams and subjective quality in patients with Myasthenia gravis. Neuropsychobiology 2004; 50:21-7. [CrossRef] [PubMed]

23. Stepansky R, Weber G, Zeithofer J. Sleep apnea and cognitive dysfunction in myasthenia gravis. Acta Med Austriaca 1997; 24:128-31. [PubMed]

24. Tasciar NF, Saracli O, Kurcer MA, Ankarali H, Emre U. Is there any relationship between quality of life and polysomnographically detected sleep parameters/disorders in stable myasthenia gravis? Acta Neurol Belg 2017; 118(1):29-37. [CrossRef] [PubMed]

25. Basta IZ, Pekmezovic TD, Peric SZ, Ksic-Tepavecovic DB, Rakocевич-Štojanovic VM, Stivic ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurul Sci 2012; 33:1375-81. [CrossRef] [PubMed]

26. Elsais A, Wyller VB, Loge JH, Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol 2013; 13(1):132. [CrossRef] [PubMed]

27. Franzen PL, Buyssee DJ. Sleep in psychiatric disorders. In: Chokroverty S, eds. Sleep disorders medicine: basic science, technical considerations and clinical aspects, 3rd edn. Philadelphia:Saunders Elsevier; 2009: 538-50. [CrossRef]

28. Jones SM, Gwathmey KG, Burns TM. Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms. Clin Exp Neurommunol 2015; 6(1):32-9. [CrossRef]

29. Fernandez-Mendoza J, Calhoun SL, Bixler EO, Karatarkan M, Liao D, Vela-Bueno A et al. Sleep misperception and chronic insomnia in the general population: role of objective sleep duration and psychological profiles. Psychosom Med 2011; 73(1):88-97. [CrossRef] [PubMed]

30. Paradis CM, Friedman S, Lazar RM, Kula RW. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry 1993; 150:1102-4. [CrossRef] [PubMed]

31. Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988; 77(4):443-5. [CrossRef] [PubMed]
KVALITET SPAVANJA KOD BOLESNIKA SA MIJASTENIJOM GRAVIS

Jelena Stojanov¹,³, Aleksandar Stojanov²,³, Iva Binić³, Jovana Antonijević³, Martin Popević⁴,⁵

¹Specijalna bolnica za psihijatrijske bolesti “Gornja Toponica”, Niš, Srbija
²Klinika za neurologiju, Klinički centar Niš, Niš Srbija
³Univerzitet u Nišu, Medicinski fakultet, Niš, Srbija
⁴Univerzitet u Beogradu, Medicinski fakultet Beograd, Srbija
⁵Institut za medicinu rada Srbije, Beograd, Srbija

Kontakt: Jelena Stojanov
Specijalna bolnica za psihijatrijske bolesti “Gornja Toponica”, Stevana Sindelica 39, 18202 Gornja Toponica, Srbija
E-mail: jelena.a.86.ja@gmail.com

Miastenija gravis (MG) je hronična neuromišićna bolest koja dovodi do progresivnog zamora, slabosti skeletnih mišića i često je povezana sa psihičkim izmenama, posebno sa lošijim kvalitetom spavanja.

Cilj rada bio je proceniti kvalitet spavanja kod bolesnika koji boluju od MG u odnosu na sociodemografske i kliničke karakteristike oboljenja.

Ukupno 70 odraslih bolesnika klasifikovano je prema klasifikaciji Američke fondacije za MG i podeljeno u grupe u odnosu na starost kada su tegobe počele, pol, zaposlenost i vrstu posla kojom se bave, prisustvo ili odsustvo patoloških promena na timusu i prisustvo ili odsustvo anti-nAchr antitela. Težina kliničkog ispoljavanja procenjena je korišćenjem kvantitativnog MG skora i MG kompozitnog skora. Pored Pittsburgovog upitnika za procenu kvaliteta spavanja, korišćene su i Hamiltonove skale za procenu anksioznosti i depresije, kao i upitnici za procenu kvaliteta života.

Rezultati našeg istraživanja pokazali su korelaciju između lošijeg kvaliteta spavanja i dužeg trajanja bolesti, patoloških promena na timusu i positivnih anti-nAchr antitela. Potvrđena je korelacija između lošijeg kvaliteta spavanja i težeg kliničke slike, lošeg kvaliteta života, anksioznosti i depresije. Kvalitet spavanja narušen je kod pacijenata sa MG, posebno kod težeg kliničkog ispoljavanja i dužeg trajanja bolesti. U odsustvu literature, bolje razumevanje prevalencije i ozbiljnosti poremećaja spavanja kod MG zahteva dalja istraživanja.

Acta Medica Medianae 2019;58(3):32-39.

Ključne reči: miastenija gravis, kvalitet spavanja